Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Esperion Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Esperion Therapeutics, Inc.

ESPR

Esperion Therapeutics, Inc.

About Esperion Therapeutics, Inc.

Esperion Therapeutics is a biopharmaceutical company focused on developing and commercializing oral, non-statin medicines to lower LDL cholesterol and reduce cardiovascular risk. Its flagship products, NEXLETOL and NEXLIZET, target patients with hyperlipidemia, statin intolerance, or high cardiovascular risk. The company leverages partnerships, clinical trials, and a strong pipeline to address unmet medical needs in cardiovascular disease prevention.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Esperion Therapeutics, Inc.

1
1
Esperion Therapeutics, Inc. Esperion Therapeutics Reports 23.3% Revenue Growth in Q1 2026, Net Loss Improves

Via official filing (AI summary) | 27 days ago | 0 comments

2
1
Esperion Therapeutics, Inc. Esperion Therapeutics Reports 2025 Financial Results and Strategic Developments

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Esperion Therapeutics, Inc. Esperion Therapeutics Reports $87.3 Million Revenue in Q3 2025, Despite $31.3 Million Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Esperion Therapeutics, Inc. Esperion Therapeutics Reports 12% Revenue Growth to $82.4 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Esperion Therapeutics, Inc. Esperion Therapeutics Reports $40.5 Million Net Loss in Q1 2025 Amid Revenue Decline

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Esperion Therapeutics, Inc. Esperion Therapeutics Reports $51.7 Million Net Loss for 2024, Improved from $209.2 Million in 2023

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Esperion Therapeutics, Inc. Esperion Therapeutics Reports Significant Revenue Growth and Improved Financials in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments